Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Heart Lung. 2013 Jul-Aug;42(4):257-61. doi: 10.1016/j.hrtlng.2012.12.008. Epub 2013 Jan 7.

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure.

Author information

  • 1Cardiovascular Center, University of Michigan Health System, Ann Arbor, MI 48109-5853, USA.

Abstract

OBJECTIVES:

To determine whether risk for implantable cardioverter-defibrillator (ICD) therapy varies by body mass index (BMI) in systolic heart failure (HF).

BACKGROUND:

It is unknown whether obesity increases sudden death risk in patients with systolic HF.

METHODS:

Secondary analysis of patients with HF, left ventricular ejection fraction ≤0.40 and ICD (N = 464) was performed using Cox regression modeling to assess risk for first delivered ICD therapy, with patients grouped by BMI (kg/m(2)): normal (18.5 to <25), overweight (25 to <30), and obese (≥30).

RESULTS:

Overweight patients, compared with patients with normal BMI, had greater adjusted risk for first ICD therapy (HR 1.66; 95% CI 1.02-2.71; P = 0.04), whereas obese BMI was not associated with risk for first ICD therapy.

CONCLUSIONS:

There was an inverted U-shaped relationship between BMI and risk for first ICD therapy among systolic HF patients, with highest risk in overweight BMI.

Copyright © 2013 Elsevier Inc. All rights reserved.

KEYWORDS:

ACE; ARB; BMI; Body mass index; HF; Heart failure; ICD; Implantable cardioverter-defibrillator; Risk stratification; UMHS; University of Michigan Health System; VAD; aldosterone receptor blocker; angiotensin converting enzyme; body mass index; heart failure; implantable cardioverter-defibrillator; ventricular assist device

PMID:
23306169
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk